What Oncolytics Biotech Inc.’s FDA meeting means for pelareorep commercialization
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care
Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.
How Incyte’s retifanlimab approval could reshape first-line therapy for advanced anal cancer in Europe
European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.